Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging

Kymera Therapeutics, Inc. (KYMR) reported a first-quarter 2025 loss of 82 cents per share, narrower than the Zacks Consensus Estimate of a loss of 92 cents. In the year-ago quarter, Kymera reported a loss of 69 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)The year-over-year deterioration was due to higher R&D expenses.Collaboration revenues totaled $22.1 million, which beat the Zacks Consensus Estimate of$10 million.In the year-ago quarter, Kymera earned collabo ...